PLK1: Orchestrating G2/M Entry and Centrosome Maturation
Polo-like kinase 1 (PLK1; encoded by PLK1 on chromosome 16p12; serine/threonine kinase; MW ~68 kDa; named after the Drosophila polo gene) is one of the most important mitotic kinases in mammalian cells, with essential non-redundant roles from late G2 phase through cytokinesis. Its activity is regulated at multiple levels: protein expression (near-zero in G0/G1, rising sharply in S/G2/M; driven by FOXM1 and E2F transcription factors), phosphorylation status (PLK1 Thr210 phosphorylation in the T-loop by Aurora A, required for full kinase activity; assisted by the PLK1-Aurora A-BORA complex at centrosomes), and substrate recruitment via its polo-box domain (PBD; a C-terminal protein-protein interaction module that binds phosphoserine/phosphothreonine motifs, directing PLK1 to pre-phosphorylated substrates). At G2/M entry, PLK1 co-operates with CDK1/cyclin B1 in a bistable positive feedback loop: PLK1 phosphorylates CDC25C (the phosphatase that activates CDK1 by removing inhibitory Thr14/Tyr15), while active CDK1 in turn phosphorylates and activates PLK1. This mutual activation creates an irreversible commitment to mitosis once the threshold is crossed. PLK1 then drives centrosome maturation (phosphorylation of pericentrin and ninein; recruitment of γ-tubulin ring complexes; bipolar spindle nucleation), kinetochore assembly (phosphorylation of Sgo1/shugoshin, protecting centromeric cohesion; PBIP1/KNL1 scaffolding), and ultimately cytokinesis (phosphorylation of PRC1, regulating central spindle formation).
Aurora A and Aurora B: Distinct Roles in Spindle Fidelity
Aurora A (AURKA; encoded by AURKA on chromosome 20q13; also known as STK15/BTAK; a frequent amplification target in breast, colorectal, and ovarian cancers) localises to centrosomes and spindle poles, where its primary functions are bipolar spindle formation and centrosome separation. Aurora A Thr288 autophosphorylation in the T-loop is required for activity and is used as a proxy readout. Beyond spindle function, Aurora A stabilises the N-Myc protein (MYCN; neuroblastoma amplification target) and c-Myc by phosphorylating them at Ser62 (c-Myc) or equivalent sites, inhibiting their ubiquitin-mediated proteasomal degradation. This Aurora A-MYCN axis makes Aurora A a target not only in epithelial cancers but specifically in neuroblastoma with MYCN amplification. Aurora B (AURKB; chromosome 17p13) operates as the catalytic core of the chromosomal passenger complex (CPC; Aurora B + INCENP + Survivin (BIRC5) + Borealin/CDCA8). The CPC moves from centromeres in prophase to the central spindle midzone in anaphase, following chromosomal segregation. Aurora B’s central mitotic function is enforcing the spindle assembly checkpoint (SAC): Aurora B phosphorylates Ndc80/HEC1 at kinetochores, destabilising incorrect (syntelic or merotelic) microtubule-kinetochore attachments; the resulting unattached kinetochores generate the “wait anaphase” signal by catalytically generating the mitotic checkpoint complex (MCC; MAD2, BubR1/BUBR1, Bub3, CDC20). MCC inhibits the anaphase-promoting complex/cyclosome (APC/C-CDC20), preventing securin and cyclin B1 degradation until all kinetochores are correctly bi-oriented.
CDK1/Cyclin B1 Activation and the SAC
CDK1 (cyclin-dependent kinase 1; Cdc2; the universal mitotic kinase; forms the maturation-promoting factor MPF when bound to cyclin B1) is the master trigger of mitotic entry. CDK1/cyclin B1 accumulates in the cytoplasm through S and G2 phases in an inactive form (Thr14/Tyr15 phosphorylated by WEE1 kinase and Myt1; these are inhibitory marks). At the G2/M transition, CDC25B (centrosomal; first wave) and CDC25C (cytoplasmic/nuclear) phosphatases dephosphorylate Thr14/Tyr15, activating CDK1. CDK1 then phosphorylates hundreds of mitotic substrates. The CDK1-PLK1 positive feedback loop described above is activated; additionally CDK1 phosphorylates lamin B1 (nuclear lamina dissolution), condensin (chromosome compaction), and hundreds of centrosome, kinetochore, and spindle proteins. WEE1 kinase is the G2 checkpoint enforcer: DNA damage activates ATM/ATR → CHK1/CHK2 → CDC25A/C phosphorylation and degradation → CDK1 remains inhibited → G2 arrest. Spirulina’s AMPK activation is relevant here: AMPK has been shown to phosphorylate and activate WEE1-like PKMYT1 in some contexts and more robustly to inhibit CDC25A stability, contributing to G1 arrest that upstream prevents S-phase entry, rather than acting directly at G2/M. AMPK also activates p21Cip1 (CDKN1A) transcription through p53-independent mechanisms, reinforcing G1 and potentially G2 checkpoints in a CDK-inhibitor-dependent manner.
How Spirulina’s AMPK and NF-κB Effects Reach the Mitotic Machinery
Spirulina does not directly bind PLK1, Aurora A, Aurora B, or CDK1 at any established pharmacological site. Its influence on mitotic progression in cancer cells is indirect, mediated through two converging upstream pathways. First, AMPK activation (phycocyanin and polysaccharide components activate AMPK, likely through a combination of partial mitochondrial Complex I modulation increasing the AMP:ATP ratio, and direct allosteric effects): AMPK phosphorylates CDC25C Ser216 (creating a 14-3-3 binding site, sequestering CDC25C in the cytoplasm and preventing CDK1 activation) in several cell line models. AMPK also suppresses mTORC1, reducing translation of cyclin B1 and PLK1 mRNA (both are highly cap-dependent; mTORC1 activates 4E-BP1 and S6K, enhancing translation of 5′-capped structured mRNAs including cyclin B1). Reduced cyclin B1 protein directly diminishes the CDK1/cyclin B1 complex available for mitotic entry. Second, NF-κB suppression (phycocyanin’s IKKβ inhibition): NF-κB transcriptionally activates BIRC5 (survivin; the Aurora B-CPC component that protects Aurora B from proteasomal degradation in mitosis) and several Aurora A-stabilising heat shock proteins (HSP90; Aurora A is an HSP90 client protein; NF-κB drives HSP90 co-chaperone expression including HSP27/HSPB1). Reduced survivin expression destabilises the CPC and reduces Aurora B activity, moderating the SAC stringency in cancer cells already expressing dysfunctional SAC components. Reduced HSP90 chaperone capacity leaves Aurora A more vulnerable to ubiquitin-mediated degradation. These effects have been observed in cancer cell models (HeLa, MCF-7, HepG2): phycocyanin at 10–50 μM reduces PLK1 mRNA 30–50%, cyclin B1 protein 20–40%, and increases G2/M arrest frequency 1.5–2.5-fold within 48 hours.
Cancer Cells vs Normal Proliferating Cells: Why the Selectivity May Exist
A critical question for any dietary compound with mitotic effects is whether it preferentially affects cancer cells or whether it also impairs normal, healthy dividing cells (intestinal crypts, bone marrow, hair follicles). Several mechanistic arguments suggest relative selectivity toward cancer cells, though none provide absolute specificity. First, cancer cells typically over-express PLK1, Aurora A, and survivin well beyond normal tissue levels; their survival is more dependent on these kinases than normal cells that have intact G1 checkpoints (Rb/p16/p21 pathways). A reduction in PLK1 that is sub-lethal for a normal epithelial cell with a robust G1 checkpoint may be lethal for a p53-null cancer cell that has already by-passed G1 and is wholly dependent on the G2/M checkpoint. Second, cancer cells with underlying SAC defects (common in CIN-high cancers: colorectal, ovarian) already have a weakened BubR1/MAD2 axis; further reduction in Aurora B/survivin via NF-κB suppression pushes them toward mitotic catastrophe (aberrant mitosis → cytokinesis failure → multipolar mitosis → massive aneuploidy → cell death), while normal cells with intact SAC tolerate the reduced SAC stringency. Third, AMPK activation has a well-documented cytoprotective effect in normal cells under metabolic stress, contrasting with the growth-suppressive effect in cancer cells with constitutively active mTORC1. These arguments are mechanistically coherent but not proven to translate to clinical selectivity at dietary spirulina doses; plasma phycocyanin concentrations from supplementation fall orders of magnitude below the in-vitro concentrations demonstrating these effects.
Scope Limitations and Practical Perspective
Honest translation of this mechanistic picture to clinical practice requires stating plainly what the evidence does and does not support. Spirulina consumed at dietary doses (3–10 g/day) has not been shown in any human trial to reduce tumour cell division, alter PLK1 or Aurora kinase activity in vivo, or improve oncological outcomes through direct mitotic effects. The in-vitro data discussed above operates at concentrations not achievable systemically through oral supplementation. The AMPK-mediated cell cycle effects are real at the cellular level but represent one part of a broad metabolic reprogramming whose primary clinical significance is in metabolic syndrome, insulin resistance, and inflammation, not oncology. What spirulina does meaningfully contribute in cancer-adjacent biology is NF-κB suppression (reducing pro-inflammatory cytokines that support tumour microenvironments), Nrf2 activation (reducing oxidative DNA damage that drives mutagenesis), and modest autophagy promotion (clearing damaged proteins and organelles, a dual-edged effect in cancer). The PLK1/Aurora kinase pathway represents a scientifically rigorous mechanistic downstream consequence of those upstream effects, but current evidence does not support spirulina as a meaningful mitotic inhibitor in any clinical context. People with cancer should treat spirulina as a nutritional supplement with genuine anti-inflammatory and antioxidant benefits, not as a substitute for validated anti-mitotic therapies.